Anemia Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR by 2036 | DelveInsight

DelveInsight's 'Anemia Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Anemia, historical and forecasted epidemiology, as well as the Anemia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the Anemia Treatment Market Report @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Anemia Market Report
• In April 2026, Johnson & Johnson announced that the US FDA granted Priority Review to the supplemental Biologics License Application (sBLA) for nipocalimab (IMAAVY), confirming the urgent need for treatment options in wAIHA.
• In February 2026, Sanofi announced rilzabrutinib, was granted Breakthrough Therapy Designation (BTD) by the US FDA for the treatment of patients with wAIHA. The Japanese Ministry of Health, Labour and Welfare has also provided rilzabrutinib an Orphan Designation (ODD) for the same condition.
• In February 2026, Ayrmid announced presentation of additional positive results for OMISIRGE in treating SAA at TANDEM 2026.
• Globally, it is estimated that ∼40% of all children aged 6-59 months, ∼37% of pregnant women and ∼30% of women 15-49 years of age are affected by anemia.
• Iron deficiency remains the leading cause of anemia globally, accounting for roughly half of all cases. It disproportionately affects women under the age of 50, who represent the most impacted population group.
• Aplastic Anemia accounted for ∼2,600 cases in the 7MM in 2025.
• Anemia prevalence was lowest in children ages 2-11 (∼5%) and highest in adults 60 and older (∼13%).
• Japan accounted for approximately 12 million cases of IDA in 2025.
• The leading Anemia Companies include Ayrmid, Teva Pharmaceuticals, Agios Pharmaceuticals, Sanofi, Astellas, Johnson & Johnson, Cellenkos, and others.
• Promising Anemia Therapies include OMISIRGE, ALVAIZ, AQVESME/PYRUKYND, Rilzabrutinib, IMAAVY, Roxadustat, CK0801, and others.

Get a Free sample for the Anemia Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Anemia Overview
Anemia is a condition marked by a lower-than-normal number of red blood cells or haemoglobin, reducing the blood's ability to carry oxygen to tissues. It disproportionately affects women and children and, in severe cases, can impair cognitive and motor development in children and lead to complications for pregnant women and their babies. The condition arises from multiple factors, including poor nutrition, infections, chronic diseases, heavy menstrual bleeding, pregnancy-related issues, and genetic predisposition, though iron deficiency remains the most common cause.

Anemia Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Anemia
• Total Diagnosed Prevalent Cases of Anemia
• Type-specific Diagnosed Prevalent Cases of Anemia
• Gender-specific Diagnosed Prevalent Cases of Anemia
• Age-specific Diagnosed Prevalent Cases of Anemia
• Severity-specific Diagnosed Prevalent Cases of Anemia
• Total Treated Cases of Anemia

Download the report to understand which factors are driving Anemia Epidemiology trends @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Approved Therapies for Anemia
• Omidubicel (OMISIRGE): Ayrmid (Gamida Cell)

Omidubicel is the first HSCT therapy for patients with severe aplastic anemia (SAA). The therapy is indicated for adults and children aged six years and older who lack a compatible stem cell donor and undergo reduced-intensity conditioning. It was approved by the US FDA in December 2025. Omidubicel addresses the limitations of umbilical cord blood (UCB) as a source including delayed hematopoietic recovery and increased infections and provides additional graft options for patients with SAA who need HSCT.

• Eltrombopag choline (ALVAIZ): Teva Pharmaceuticals

Eltrombopag choline is an oral thrombopoietin (TPO) receptor agonist that works to increase platelet production by interacting with the transmembrane domain of the human TPO-receptor to initiate signaling cascades that induce proliferation and differentiation of megakaryocytes. In November 2023, the US FDA approved ALVAIZ for the treatment of certain forms of thrombocytopenia and SAA. ALVAIZ has been approved for ITP, Thrombocytopenia with Hep C, and SAA.

Anemia Pipeline Analysis
• Rilzabrutinib (WAYRILZ): Sanofi

Rilzabrutinib is the first BTK inhibitor for immune thrombocytopenia (ITP) that helps address the root cause of disease through multi-immune modulation. This innovative therapy is approved in the US for adults with persistent or chronic ITP who have had an insufficient response to a previous treatment. Rilzabrutinib is being studied across a variety of rare diseases, including wAIHA, IgG4-RD, and SCD. These additional indications are currently under investigation and have not been approved by regulatory authorities.

• CK0801: Cellenkos

CK0801 is a first-in-class, allogeneic, cord blood-derived T-regulatory cell product, developed from Cellenkos' proprietary manufacturing platform that overcomes immune dysfunction by inhibiting key drivers of inflammation. CK0801 contains robust regulatory T-cells derived from healthy donor cord blood units. The drug CK0801 is currently undergoing evaluation in the Phase I clinical trial.

Discover more about therapies set to grab Major Anemia Market Share @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Anemia Companies
Ayrmid, Teva Pharmaceuticals, Agios Pharmaceuticals, Sanofi, Astellas, Johnson & Johnson, Cellenkos, and others.

Anemia Market Outlook
The Anemia therapeutics market has evolved from a largely supportive care driven space into a mechanism driven, innovation led segment of hematology. Historically, management relied on nutritional supplementation and transfusion based approaches, particularly oral iron and blood transfusions, which primarily addressed symptoms rather than underlying disease biology. The introduction of erythropoiesis stimulating agents marked a major breakthrough, establishing a biologic backbone for Anemia management in chronic kidney disease and oncology settings, and they continue to remain a standard of care due to strong clinical familiarity. Over time, the market matured with incremental innovations such as improved intravenous iron formulations, although safety concerns and biosimilar competition created pricing and utilization pressures in these legacy segments.

Anemia Treatment Landscape
The Anemia treatment market has shifted toward targeted therapies with distinct mechanisms of action. The emergence of HIF PH inhibitors introduced oral alternatives that stimulate endogenous erythropoietin production through hypoxia signalling pathways, expanding treatment options beyond injectable therapies. In parallel, erythroid maturation agents such as luspatercept have redefined treatment in conditions characterized by ineffective erythropoiesis, particularly in myelodysplastic syndromes and beta thalassemia. More recently, gene and cell therapies have begun to reshape the landscape by offering potential curative approaches for hereditary anemia's, signalling a transition from chronic management to long term disease modification

To know more about Anemia Companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Anemia Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Anemia Companies- Ayrmid, Teva Pharmaceuticals, Agios Pharmaceuticals, Sanofi, Astellas, Johnson & Johnson, Cellenkos, and others.
• Anemia Therapies- OMISIRGE, ALVAIZ, AQVESME/PYRUKYND, Rilzabrutinib, IMAAVY, Roxadustat, CK0801, and others.
• Anemia Therapeutic Assessment- Anemia current marketed and emerging therapies
• Anemia Market Dynamics: Anemia market drivers and market barriers
• Anemia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Anemia Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

Explore more information about the Anemia Therapeutics Market Report @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Anemia
4. Key Events of Anemia
5. Epidemiology and Market Methodology of Anemia
6. Anemia Market Overview at a Glance
7. Disease Background And Overview of Anemia
8. Epidemiology and Patient Population of Anemia
9. Patient Journey of Anemia
10. Marketed Therapies of Anemia
11. Emerging Therapies of Anemia
12. Anemia: 7MM Analysis
13. Unmet Needs of Anemia
14. SWOT Analysis of Anemia
15. KOL Views of Anemia
16. Market Access and Reimbursement of Anemia
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.